Nnamdi Njoku's disposal reduced his direct holdings by 4%, with over half tied to tax withholding from RSU vesting. He retains ~161,223 shares worth $5.81 million.

OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.

Omnicell's 20.1% monthly slide reflects booking uncertainty, margin pressure and refresh-cycle risks despite a higher 2026 profit outlook.

In the past quarter, Omnicell, Inc. reported second-quarter 2026 revenue of US$312.21 million and net income of US$24.29 million, with both basic and diluted earnings per share from continuing operations rising compared with a year earlier, and also showed improved profitability for the first half of 2026. Omnicell also raised its full-year 2026 revenue guidance to a range of US$1.23 billion to US$1.25 billion and projected third-quarter 2026 revenue of US$301 million to US$307 million,...

Omnicell stock is currently caught between two different valuation signals. The Discounted Cash Flow (DCF) estimate points to meaningful upside to intrinsic value, while market-based multiples suggest the shares already trade at a premium. Over the past 5 years Omnicell shareholders have seen the share price fall 77.6%, which sets a cautious backdrop for any claim that the stock now offers clear value. Recent product work at subsidiary EnlivenHealth, such as the VaxReach program to support...

Omnicell highlights Titan XT and OmniSphere momentum, and raises profit outlook, while customer approval timing weighs on product bookings.

Shares of healthcare tech company Omnicell (NASDAQ:OMCL) fell 9.9% in the afternoon session after the company issued weak guidance for the upcoming quarter that overshadowed its strong second-quarter results.

Omnicell Inc (OMCL) delivers solid Q2 results with a $15 million tariff refund boosting EPS, but faces headwinds from lengthening sales cycles and a wide bookings guidance range.

Omnicell (NASDAQ:OMCL) reported second-quarter 2026 revenue at the high end of its prior outlook and profitability above expectations, while widening its full-year product bookings range to reflect uncertainty in the timing of customer purchasing decisions for large medication-management platform in

Omnicell (OMCL) delivered earnings and revenue surprises of +95.83% and +0.83%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare tech company Omnicell (NASDAQ:OMCL) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 7.4% year on year to $312.2 million. On the other hand, next quarter’s revenue guidance of $304 million was less impressive, coming in 2.9% below analysts’ estimates. Its non-GAAP profit of $0.94 per share was significantly above analysts’ consensus estimates.

Healthcare tech company Omnicell (NASDAQ:OMCL) will be announcing earnings results this Thursday morning. Here’s what investors should know.

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

OMCL heads into Q2 earnings with OmniSphere adoption, Connected Devices execution and recurring revenue growth ahead of July 30 results.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 13.3% over the past six months, topping the S&P 500 by 2.5 percentage points.

Earlier this month, Omnicell filed a US$72.384 million shelf registration for 1,600,000 common shares tied to an ESOP-related offering and elevated Chief Operating Officer Nnamdi Njoku to President, while Randall Lipps remained Chief Executive Officer and Chairman. This combination of leadership evolution and employee-focused equity issuance may influence how investors assess Omnicell’s governance, culture, and long-term execution capacity. We’ll now examine how Njoku’s expanded leadership...